Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. (ALLO) Stock Overview

Explore Allogene Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ALLO●NASDAQ
HealthcareBiotechnology
$1.74
$0.08(4.40%)
U.S. Market opens in 30h 19m

Allogene Therapeutics, Inc. (ALLO)

Meyka AI Score

Z

Key Financials

Market Cap424.3M
P/E Ratio-2.29
EPS (TTM)$-0.77
ROE-0.56%
Fundamental Analysis

AI Price Forecasts

1 Month$1.45
3 Months$2.63
1 Year Target$1.42

ALLO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Allogene Therapeutics, Inc. (NASDAQ: ALLO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Allogene Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ALLO on the NASDAQ shows an RSI of 36.22, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $1.42 for the NASDAQ listing.

Key metrics behind Allogene Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -2.29 and a market capitalization of 424.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALLO on the NASDAQ.

Price Performance (NASDAQ: ALLO)

1-Day Change
-4.40%
5-Day Change
-0.57%
1-Month Change
-15.12%
3-Month Change
-24.68%
6-Month Change
1.16%
Year-to-Date (YTD) Change
27.007%
1-Year Change
15.23%
3-Year Change
-64.78%
5-Year Change
-91.98%
All-Time (Max) Change
-93.04%

Contact Information

https://www.allogene.com
650 457 2700
210 East Grand Avenue, South San Francisco, CA, 94080

Company Facts

1,520 Employees
IPO DateOct 11, 2018
CountryUS
Actively Trading

Frequently Asked Questions